Regatta Capital Group LLC Grows Holdings in Cencora, Inc. (NYSE:COR)

Regatta Capital Group LLC boosted its stake in Cencora, Inc. (NYSE:COR) by 2.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,750 shares of the company’s stock after purchasing an additional 174 shares during the period. Regatta Capital Group LLC’s holdings in Cencora were worth $1,966,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COR. Concord Wealth Partners purchased a new stake in Cencora during the 3rd quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after acquiring an additional 69 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at $41,000. Modus Advisors LLC acquired a new position in shares of Cencora during the fourth quarter worth $54,000. Finally, Carolina Wealth Advisors LLC increased its holdings in Cencora by 366.7% in the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after buying an additional 209 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.2 %

Shares of COR opened at $248.45 on Friday. The stock’s fifty day simple moving average is $237.51 and its 200-day simple moving average is $234.75. The firm has a market capitalization of $48.02 billion, a PE ratio of 33.08, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.89%. Cencora’s payout ratio is 29.29%.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,187 shares of company stock worth $17,790,912. Insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday. Evercore ISI increased their target price on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Robert W. Baird boosted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $277.00.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.